March 2021 Archives by subject

• Messages sorted by: [ thread ] [ author ] [ date ]
• More info on this list...

Starting: Mon Mar 1 03:39:30 PST 2021
Ending: Wed Mar 31 10:54:26 PDT 2021
Messages: 71

• [Ip-health] "Letter to Humanity" - petition from Brazil re accountability for Brazilian government response to the pandemic   Cathy Rowan
• [Ip-health] 10 March 2021: South Africa raises the banner for the TRIPS waiver at the WTO   Thiru Balasubramaniam
• [Ip-health] 23 February 2021: South Africa’s interventions at the WTO TRIPS Council   Paul Fehlner
• [Ip-health] AP: Countries call on drug companies to share vaccine know-how   Thiru Balasubramaniam
• [Ip-health] Bicameral Effort to Stop Proposed Rule Undermining Long-Standing Tool to Restrain Price Gouging for Taxpayer-Funded Drugs | Congressman Lloyd Doggett   James Love
• [Ip-health] Biden Can’t Correct Vaccine Apartheid on Big Pharma’s Terms   Baker, Brook
• [Ip-health] BMJ: Covid-19, trust, and Wellcome: how charity’s pharma investments overlap with its research efforts   Kavian Kulasabanathan
• [Ip-health] Bolivia intends to use Article 31bis TRIPS as an importing member   Heesob Nam
• [Ip-health] Buying Know-How to Scale Vaccine Manufacturing | by James Love | Mar, 2021 | Medium   James Love
• [Ip-health] Buying Know-How to Scale Vaccine Manufacturing | by James Love | Mar, 2021 | Medium   Paul Fehlner
• [Ip-health] Canadian Biolyse Seeks to Manufacture COVID-19 Vaccines and may test Canada's Compulsory License Regime   Arianna Schouten
• [Ip-health] Canadian company pursues compulsory license to distribute Covid-19 vaccine to low-income countries   Ed Silverman
• [Ip-health] Can the Next USPTO Director Bring Equity to the Patent System?   Priti Krishtel
• [Ip-health] Can the “Third Way” Ensure Equitable Access to COVID-19 Vaccines for All Countries?   Sangeeta Shashikant
• [Ip-health] Can the “Third Way” Foster Technology Transfer to Fight COVID-19 Globally?   Sangeeta Shashikant
• [Ip-health] CNBC: White House weighs temporarily lifting intellectual property shield on Covid-19 vaccines   Thiru Balasubramaniam
• [Ip-health] Covid: UK fighting patent-free Covid vaccine proposals - BBC Newsnight   Thiru Balasubramaniam
• [Ip-health] DNDi strategic plan webinar - please join us   James Arkinstall
• [Ip-health] Ecuador grants compulsory license over HIV drug raltegravir   Luis Gil Abinader
• [Ip-health] Expanding Vaccine Manufacturing Capacity Solely Within the Pharma Cartel is a Recipe for Perpetual Vaccine Apartheid and Artificial Scarcity   Baker, Brook
• [Ip-health] Foreign Policy: To Democratize Vaccine Access, Democratize Production   Matthew Kavanagh
• [Ip-health] Guardian: World's poorest face vaccine delays through Covax programme   Thiru Balasubramaniam
• [Ip-health] Hungarian compulsory license for remdesivir raises a stir with BIO, PhRMA and the US Chamber of Commerce   Thiru Balasubramaniam
• [Ip-health] IAM's 9 Mar 2021 article "Covid-19 patent landscape confusion is a big concern for life sciences organisations"   Aleksandr Belinskiy
• [Ip-health] KEI comments to NIST on Reasonable Terms as basis for March-in Bayh-Dole Act, 18 March 2021   James Love
• [Ip-health] KEI Letter to New WTO Director-General on COVID-19 Response   Thiru Balasubramaniam
• [Ip-health] KEI Response to Questions from USTR on Special 301 - March 5, 2021 | Knowledge Ecology International   James Love
• [Ip-health] Letter: U.S. leverage over vaccine patent could expand NIH-Moderna vaccine production   Peter Maybarduk
• [Ip-health] License to NIH Spike Protein Technology Needed in COVID-19 Vaccines Demonstrates “Available to the Public on Reasonable Terms” Requirement   kathryn ardizzone
• [Ip-health] March 15 - WHO, USP, Sabin Institute COVID-19 Vaccine Equity & Quality Webinar   Amy Meng
• [Ip-health] MSF/DNDi webinar (Friday, Feb 26): TRIPS waiver for COVID19 tools-- what are the implication for Africa?   Yuanqiong HU
• [Ip-health] MSF briefing note: Canada position on compulsory license in the context of the TRIPS waiver negotiation   Yuanqiong HU
• [Ip-health] My NIST comments on the definition of Subject Invention, 26 March 2021   Luis Gil Abinader
• [Ip-health] New Episode of Talk is the Best Medicine Podcast on March 16th with Dr. David Ridley   Global Health Impact Project
• [Ip-health] New ReAct report: Governments need to take more leadership to ensure global sustainable access to effective antibiotics   Helle Aagaard
• [Ip-health] New resource: research synthesis on compulsory licensing   Marcela Vieira
• [Ip-health] New South Centre Paper: The TRIPS waiver proposal: an urgent measure to expand access to the COVID-19 vaccines   Anna Bernardo
• [Ip-health] NEW South Centre Policy Brief: Competition Regulation in Healthcare in South Africa   Anna Bernardo
• [Ip-health] NEW South Centre Policy Brief: Need for Extension of the LDC Transition Period Under Article 66.1 of the TRIPS Agreement Until Graduation and Beyond   Anna Bernardo
• [Ip-health] New York Times: India Cuts Back on Vaccine Exports as Infections Surge at Home   Thiru Balasubramaniam
• [Ip-health] New York Times: Rich Countries Signed Away a Chance to Vaccinate the World   Thiru Balasubramaniam
• [Ip-health] NYU School of Law "Access to Medicine: The Role and Impact of U.S. Innovation Policy" Online Conference (Wed, March 10, 2021 12:00 PM – 5:00 PM EST   Aleksandr Belinskiy
• [Ip-health] Op-ed by the Polish PM in Politico: EU must use every legal tool to boost vaccine production   Thiru Balasubramaniam
• [Ip-health] Open Lecture on Pharmaceutical innovation: Replacing monopolies with health impact rewards   Heesob Nam
• [Ip-health] Open Position: DNDi Policy Manager   Rachel M. Cohen
• [Ip-health] Pfizer and BioNTech Profiteering Exposed – More than Enough is Enough   Baker, Brook
• [Ip-health] please post - thank you   Ed Silverman
• [Ip-health] Press Release--UAEM Report Card: U.S. Universities Fall Short on their Commitment to Ensuring access to Publicly-funded medicines and Combatting the Coronavirus   Merith Basey
• [Ip-health] Press release: Access to Corona vaccination only for the rich   Christiane Fischer
• [Ip-health] REMINDER: South Centre Series on Manufacturing Capacity for Covid-19 Vaccines: The Experience of Butantan-Sinovac, 23 March 2021   Anna Bernardo
• [Ip-health] Reminder Webinar Mar 25 - Non-commercial pharmaceutical R&D: What do PDPs suggest about costs and efficiency?   Marcela Vieira
• [Ip-health] Report on Financing for Local Pharmaceutical Production in Africa   Frederick Abbott
• [Ip-health] Report on Financing for Local Pharmaceutical Production in Africa   James Love
• [Ip-health] Rich countries' stance on local production of vaccines: Smoke and mirrors   Priti Patnaik
• [Ip-health] SAVE THE DATE 17th March 15 CET No Business as Usual: Challenging the IP Protection Framework Now and After COVID-19   Jaume Vidal
• [Ip-health] South Centre Series on Manufacturing Capacity for Covid-19 Vaccines: The Experience of Butantan-Sinovac   Anna Bernardo
• [Ip-health] Statement: U.S. Dose Sharing w/Mexico No Substitute for Increased Manufacturing   Peter Maybarduk
• [Ip-health] STAT News: Pharma mergers face fresh scrutiny by the FTC and a new international antitrust working group   Ed Silverman
• [Ip-health] Trump gave drug companies a last-minute win on prescription prices. Democrats want Biden to roll it back.   Claire Cassedy
• [Ip-health] TWN Info: Seven countries urge WTO DG to hold direct talks with Big Pharma   Sangeeta Shashikant
• [Ip-health] TWN Info: South countries demand text-based negotiations on TRIPS waiver   Chee Yoke Ling
• [Ip-health] TWN Info: Strong support for TRIPS waiver amidst opposition by Big Pharma   Chee Yoke Ling
• [Ip-health] Unredacted Pfizer contract with Dominican Republic, shows broad indemnity provisions for COVID-19 vaccine sales   Luis Gil Abinader
• [Ip-health] Vaccine nationalism and WTO Disputes   Priti Patnaik
• [Ip-health] Von der Leyen 'not ruling out' waiving IP rights on vaccines   Dimitri Eynikel
• [Ip-health] Wall Street Journal (Editorial Board): Watch Out for a Vaccine Patent Heist   Thiru Balasubramaniam
• [Ip-health] Washington Post: Drug companies defend vaccine monopolies in face of global outcry   Thiru Balasubramaniam
• [Ip-health] Webinar - March 25 - Non-commercial pharmaceutical R&D: What do PDPs suggest about costs and efficiency?   Marcela Vieira
• [Ip-health] WHO donors seek a new tech transfer hub under ACT-A, C-TAP sidelined   Priti Patnaik
• [Ip-health] WSJ: FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers   Thiru Balasubramaniam
• [Ip-health] WTO DG to Meet with Big Pharma   Sangeeta Shashikant

Last message date: Wed Mar 31 10:54:26 PDT 2021
Archived on: Wed Mar 31 10:58:13 PDT 2021

• Messages sorted by: [ thread ] [ author ] [ date ]
• More info on this list...